Frederic Rahbari Oskoui MD
Overview
Frederic Farid Rahbari-Oskoui, MD, MS is a practicing nephrologist and the director of Polycystic Kidney Disease Center of Excellence at Emory University.
Dr. Rahbari attended medical school at Universit de Bordeaux in France and obtained his MD (magna cum laude) in 1997 after completing a residency program in general medicine and partial nephrology training at the same institution. He worked as an attending physician in Normandy, France for two years before moving to the United States. Dr. Rhabari spent two years in clinical and translational research on oxidative stress, both at Universit de Bordeaux and at New York Medical College. He subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons from 2000-2003 and completed his academic track fellowship in nephrology at Emory University from 2003-2006, including an additional year in cystic and inherited diseases of the kidneys.
He joined the faculty at Emory University School of Medicines Division of Renal Medicine in July of 2006 at the rank of instructor. He was named an assistant professor of medicine in 2007 and an associate professor of medicine in 2014. During this time, he also obtained a master of science in clinical research (MSCR) degree from Emory University.
Dr. Rahbari is a diplomat of the American Board of Internal Medicine and is board-certified in nephrology.
He specializes in cystic diseases of the kidneys, inherited diseases of the kidneys, hypertension, ambulatory blood-pressure monitoring, and imaging in renal diseases, and he is involved in caring for patients with kidney diseases as well as conducting research in those fields.
He has co-authored more than 50 original manuscripts, review articles, and textbook chapters and is a regular author for UpToDate on cystic diseases of the kidneys and polycystic kidney disease.
He is a Fellow of the American Society of Nephrology, a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation, a member of the Emory University Promotions and Tenure Committee, and a member of the HALT-PKD Trial Steering Committee and the SPRINT Trial Publication and Presentations Committee.
He has been (and/or continues to be) an investigator in several landmark trials and observational cohorts:
1- HALT-PKD trial: Multi-center, randomized double-blind placebo controlled trial of multi-level blockage of the RAAS by ACE-I +/- ARBs in ADPKD (2004-2014)
2- TEMPO and REPRISE trials: Safety and Efficacy of the Vasopressin receptor antagonist Tolvaptan in ADPKD (2005-present)
3- The Systolic Blood pressure trial (SPRINT trial)
4- Consortium for Radiologic Imaging of Polycystic Kidney disease: CRISP
5- MUSE trial
6- The Melatonin in night-time blood pressure in African-Americans (MAP) trials
7- Pharmacogenomics of Essential Hypertension (PEAR trial)
8- PKD cohort study: Observational cohort of ADPKD patients followed for seven years
Academic Appointment
- Professor of Medicine, Medicine-Renal, Emory Univeristy SOM
- Master Clinician, Department of Medicine, Emory University School of Medicine
- Associate Professor of Medicine, Medicine - Renal Medicine, Emory University School of Medicine
- Instructor of Medicine, Department of Medicine-Renal Division, Emory University School of Medicine
Education
Degrees
- The Third Cycle of French Medical Studies: (Residency in General Medicine and Doctoral Thesis) from University of Bordeaux-II
- The Second Cycle of French Medical Studies, (Clinical Sciences) from Paul Broca School of Medical Sciences at the University Victor Segalen
- The First Cycle of French Medical Studies, (Basic Sciences) from University of Bordeaux II
- Master of Science in Clinical Research from T. Laney Graduate School Emory University
- MD from University of Bordeaux-II France
Research
Focus
- 1) Polycystic kidney disease: Clinical trials to halt progression of disease (HALT-PKD and four TEMPO trials), and observational cohorts on natural progression of disease (CRISP, Overture cohorts) 2) Ambulatory blood pressure monitoring (in ADPKD and essential hypertension). 3) Role of Melatonin on nocturnal hypertension. 4) Pharmacogenomics of response to antihypertensive therapy.
Publications
-
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 20 Page(s): 520 - 528
04/01/2025 Authors: Nowak KL; Copeland TP; Ku E; Sarnak MJ; Gitomer B; Abebe KZ; Chapman A; Perrone R; Rahbari-Oskoui FF; Steinman T -
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials.
Am J Kidney Dis Volume: 85 Page(s): 127 - 130
01/01/2025 Authors: Ku E; Copeland TP; McCulloch CE; Abebe KZ; Chonchol M; Perrone RD; Rahbari-Oskoui FF; Yu ASL; Steinman T; Chapman A -
Polycystic Kidney Disease Diet: What is Known and What is Safe.
Clin J Am Soc Nephrol Volume: 19 Page(s): 664 - 682
05/01/2024 Authors: Chebib FT; Nowak KL; Chonchol MB; Bing K; Ghanem A; Rahbari-Oskoui FF; Dahl NK; Mrug M -
Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT.
Clin J Am Soc Nephrol Volume: 19 Page(s): 213 - 223
02/01/2024 Authors: Drawz PE; Lenoir KM; Rai NK; Rastogi A; Chu CD; Rahbari-Oskoui FF; Whelton PK; Thomas G; McWilliams A; Agarwal AK -
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Lancet Diabetes Endocrinol Volume: 12 Page(s): 51 - 60
01/01/2024 Authors: EMPA-KIDNEY Collaborative Group -
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Lancet Diabetes Endocrinol Volume: 12 Page(s): 39 - 50
01/01/2024 Authors: EMPA-KIDNEY Collaborative Group -
Management of Hypertension and Associated Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease.
Adv Kidney Dis Health Volume: 30 Page(s): 417 - 428
09/01/2023 Authors: Rahbari-Oskoui FF -
Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation.
Kidney Int Volume: 104 Page(s): 334 - 342
08/01/2023 Authors: Gregory AV; Chebib FT; Poudyal B; Holmes HL; Yu ASL; Landsittel DP; Bae KT; Chapman AB; Frederic R-O; Mrug M -
TESEVATINIB (KD019) VS PLACEBO FOR ADPKD: RESULTS OF A PH2B TRIAL
Volume: 81 Page(s): S102 - S102
04/01/2023 Authors: Rastogi A; Fada G; Rahbari-Oskoui F; Park M; Dahl N; Perrone R; Yang Z; Bhattacharya S; Herrera K; Eizenhamer D -
Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study.
Kidney360 Volume: 3 Page(s): 1253 - 1262
07/28/2022 Authors: Drawz PE; Rai NK; Lenoir KM; Suarez M; Powell JR; Raj DS; Beddhu S; Agarwal AK; Soman S; Whelton PK